/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
The National Security Group, Inc. Releases Financial Results
ELBA, Ala.–(BUSINESS WIRE)–The National Security Group, Inc. (NASDAQ:NSEC) results for the three
months ended March 31, 2019 and 2018, based on U.S. generally accepted
accounting principles, were reported today as follows:
Unaudited Consolidated Financial Summary | Three months ended March 31, | |||||||||
2019 | 2018 | |||||||||
Gross premiums written | $ | 16,936,000 | $ | 16,965,000 | ||||||
Net premiums written | $ | 15,600,000 | $ | 15,780,000 | ||||||
Net premiums earned | $ | 14,718,000 | $ | 15,059,000 | ||||||
Net investment income | 962,000 | 920,000 | ||||||||
Net investment gains (losses) | 2,120,000 | (264,000 | ) | |||||||
Other income | 146,000 | 161,000 | ||||||||
Total Revenues | 17,946,000 | 15,876,000 | ||||||||
Policyholder benefits and settlement expenses | 9,023,000 | 9,427,000 | ||||||||
Amortization of deferred policy acquisition costs | 980,000 | 803,000 | ||||||||
Commissions | 2,033,000 | 2,060,000 | ||||||||
General and administrative expenses | 2,332,000 | 2,003,000 | ||||||||
Taxes, licenses and fees | 687,000 | 649,000 | ||||||||
Interest expense | 295,000 | 302,000 | ||||||||
Total Benefits, Losses and Expenses | 15,350,000 | 15,244,000 | ||||||||
Income Before Income Taxes | 2,596,000 | 632,000 | ||||||||
Income tax expense | 153,000 | 161,000 | ||||||||
Net Income | $ | 2,443,000 | $ | 471,000 | ||||||
Income Per Common Share | $ | 0.97 | $ | 0.19 | ||||||
Reconciliation of Net Income to non-GAAP Measurement | ||||||||||
Net income | $ | 2,443,000 | $ | 471,000 | ||||||
Income tax expense | 153,000 | 161,000 | ||||||||
Investment (gains) losses, net | (2,120,000 | ) | 264,000 | |||||||
Pretax Income From Operations | $ | 476,000 | $ | 896,000 | ||||||
Management Commentary on Results of Operations
Summary:
For the three months ended March 31, 2019, net income for the Company
totaled $2,443,000, $0.97 income per share, compared to net income of
$471,000, $0.19 income per share, for the three months ended March 31,
2018; a year over year increase of $1,972,000. The increase in net
income was primarily driven by an increase in investment gains on our
investment in company owned life insurance. Pretax income from
operations for the first quarter of 2019 totaled $476,000 compared to a
pretax income from operations of $896,000 in the first quarter of 2018.
The primary reason for the $420,000 decrease in pretax income from
operations in the first quarter of 2019, compared to the same period in
2018, was a $341,000 decrease in net premiums earned. The decline in net
premiums earned was due to an increase in ceded premium related to
higher cost of catastrophe reinsurance in our P&C segment.
Premium Revenue:
For the three-month period ended March 31, 2019, net premiums earned
were down $341,000 at $14,718,000 compared to $15,059,000 during the
same period in 2018. The decrease in premium revenue was primarily
driven by a decline in net earned premium in the P&C segment of
$270,000. The decline in gross earned premium was primarily attributable
to a decrease in our surplus lines business in coastal Louisiana. In
addition, as mentioned previously, ceded premium was up $144,000 or
8.9%, in the first quarter of 2019, compared to the same period in 2018
due to an increase in cost of our catastrophe reinsurance.
Investment Gains (Losses):
Investment gains for the three-month period ended March 31, 2019 were
$2,120,000 compared to investment losses of $264,000 for the three-month
period ended March 31, 2018. The primary reason for the increase in
first quarter 2019 investment gains compared to the first quarter 2018
investment loss was a gain on company owned life insurance (COLI) of
$1,792,000.
In 2018, due to a change in GAAP, unrealized gains and losses on equity
investments are required to be reported as a component of investment
gains/losses on the statement of operations. These amounts were
previously reported as a component of Other Comprehensive Income. For
the three months ended March 31, 2019, investment losses include a
$126,000 increase in accumulated gains on equity securities held for
investment. This increase in accumulated gains was driven by an overall
improvement in stock market values experienced in the first quarter of
2019.
Net Income:
For the quarter ended March 31, 2019, the Company had net income of
$2,443,000, $0.97 income per share, compared to net income of $471,000,
$0.19 income per share, for the same period in 2018. The primary reason
for the increase in first quarter 2019 earnings compared to first
quarter 2018 earnings was the gain on company owned life insurance
mentioned previously.
Pretax Income from Operations:
For the three-month period ended March 31, 2019, our pretax income from
operations was $476,000 compared to a pretax income from operations of
$896,000 for the three-month period ended March 31, 2018; a decrease of
$420,000. The primary reason for the decrease in pretax income from
operations in the first quarter of 2019 compared to the same period in
2018 was a decrease in net premiums earned driven by an increase in
ceded premium related to our catastrophe reinsurance.
P&C Segment Combined Ratio:
For the quarter ended March 31, 2019, the P&C segment had a GAAP
combined ratio of 99.1%. Reported claims from cat events totaling
$955,000 combined with reported claims from non-catastrophe wind and
hail totaling $2,081,000 increased the P&C segment combined ratio in the
first quarter of 2019 by 22.9 percentage points. In comparison, for the
quarter ended March 31, 2018, the P&C segment had a GAAP combined ratio
of 97.0%. Reported claims from cat events totaling $758,000 combined
with reported claims from non-catastrophe wind and hail totaling
$1,159,000 increased the P&C segment combined ratio in the first quarter
of 2018 by 14.2 percentage points. Partially offsetting the increase in
catastrophe losses and non-cat wind and hail losses in the first quarter
of 2019 was a decrease in fire related losses of $1,289,000 compared to
the same period in the prior year.
Selected Balance Sheet Highlights |
March 31, |
December 31, |
||||||||
UNAUDITED | ||||||||||
Invested Assets | $ | 116,690,000 | $ | 112,690,000 | ||||||
Cash | $ | 7,418,000 | $ | 5,676,000 | ||||||
Total Assets | $ | 149,839,000 | $ | 144,231,000 | ||||||
Policy Liabilities | $ | 78,635,000 | $ | 77,988,000 | ||||||
Total Debt | $ | 14,355,000 | $ | 14,352,000 | ||||||
Accumulated Other Comprehensive Income (Loss) | $ | 189,000 | $ | (1,570,000 | ) | |||||
Shareholders’ Equity | $ | 49,942,000 | $ | 45,866,000 | ||||||
Book Value Per Share | $ | 19.76 | $ | 18.15 | ||||||
Management Commentary on Financial Position
Invested Assets:
Invested assets as of March 31, 2019 were $116,690,000 compared to
$112,690,000 as of December 31, 2018. The increase in invested assets
was primarily due to $1,709,000 in cash flow from operating activities
enabling additional investment in the fixed income investment portfolio.
Cash:
The Company, primarily through its insurance subsidiaries, had
$7,418,000 in cash and cash equivalents at March 31, 2019, compared to
$5,676,000 at December 31, 2018. The increase in cash in the first
quarter of 2019, compared to 2018, was due to positive cash flow from
insurance operations.
Total Assets:
Total assets as of March 31, 2019 were $149,839,000 compared to
$144,231,000 at December 31, 2018. Positive cash flow from insurance
operations contributed to an increase in purchases of fixed maturity
securities and increases in market value of or portfolio of fixed
maturity securities further contributed to the increase in total assets
for the first quarter of 2019.
Policy Liabilities:
Policy related liabilities were $78,635,000 at March 31, 2019, compared
to $77,988,000 at December 31, 2018; an increase of $647,000 or 0.8%.
The primary reason for the increase in policy liabilities in the first
quarter of 2019 compared to 2018 was an increase in unearned premium.
This increase in unearned premium is seasonal as we typically issue and
renew a larger number of annual insurance contracts during the first and
second quarters of each year compared to the remainder of the year.
Debt Outstanding:
Total debt at March 31, 2019 was virtually unchanged at $14,355,000
compared to $14,352,000 at December 31, 2018.
Shareholders’ Equity:
Shareholders’ equity as of March 31, 2019 was $49,942,000, up $4,076,000
compared to December 31, 2018 Shareholders’ equity of $45,866,000. Book
value per share was $19.76 at March 31, 2019, compared to $18.15 per
share at December 31, 2018, an increase of $1.61 per share. The primary
factors contributing to the increase in both book value per share and
Shareholders’ equity were net income of $2,443,000 and accumulated other
comprehensive income of $1,759,000. Offsetting the increase in
Shareholders’ equity was shareholder dividends of $126,000.
The National Security Group, Inc. (NASDAQ Symbol: NSEC), through |
Contacts
Brian McLeod – Chief Financial Officer @ (334) 897-2273.
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
Innocan
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
HERZLIYA, Israel and ALGARY, AB, May 9, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan’s innovative therapy provided immediate noticeable pain relief and improved mobility.
Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri’s condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her.
As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed.
“Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia,” commented Iris Bincovich, CEO of Innocan. “Once again, Innocan has shown liposomal-CBD to be effectively active for pain relief and well-being. We see this pre-clinical treatment as strong evidence of liposomal-CBD’s potential to improve the lives of animal patients and potentially human patients.”
“Laminitis is a crippling condition well familiar and common in horses,” said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan. “The disease results in severe pain condition, representing another big market for liposomal-CBD with great potential to treat horses. Innocan is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.”
For further information and a supporting video, please see: https://youtu.be/Hgqh2WOlwJQ?si=oGgSYrGi3rkW-RC
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey-302141590.html
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE2 weeks ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis5 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis4 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan4 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey